Cyclin D1 Overexpression Detected by a Simple Competitive Reverse Transcription-polymerase Chain Reaction Assay for Lymphoid Malignancies

Toshiyasu Taniguchi,1 Akira Fujita,2 Shunji Takahashi,3 Kaoru Uchimaru,1,5 Miwa Yoshikawa,1 Shigetaka Asano,4 Toshiro Fujita1 and Toru Motokura1,6

1Fourth Department of Internal Medicine, University of Tokyo, School of Medicine, 3-28-6 Mejirodai, Bunkyo-ku, Tokyo 112, 2Department of Hematology, Showa General Hospital, 2-450 Tenjin-cho, Kodaira, Tokyo 187, 3Division of Clinical Oncology, Cancer Chemotherapy Center, Cancer Institute Hospital, 1-37-1 Kamiikebukuro, Toshima-ku, Tokyo 170 and 4Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108

The D-type cyclins (cyclins D1, D2 and D3) bind to and activate cyclin-dependent kinase 4 (or 6) and then the activated kinase phosphorylates the Rb protein and facilitates G1 phase progression toward the S phase.1, 2) All three human D-type cyclin genes encode small (33–34 kDa) proteins that share an average of 57% identity over the entire coding region and 78% in the cyclin box.3, 4) Among the D-type cyclins, the cyclin D1 gene was identified as a putative oncogene, designated PRAD1,5) bcl-1, an oncogene at the breakpoint on 11q13 of the t(11;14)(q13;q32) translocation frequently observed in B-cell malignancies, proved to be the cyclin D1/PRAD1 gene.6) t(11;14)(q13;q32) and its molecular counterpart, bcl-1 rearrangement, leads to cyclin D1 overexpression, presumably because of the regulatory segment of the juxtaposed immunoglobulin gene.6, 7) These abnormalities were detected in 6% of B-cell lymphomas,9, 7) 3% of plasma cell disorders,9, 10) 18% of prolymphocytic leukemia (PLL),11) and 6% of chronic lymphocytic leukemia (CLL).8, 12) Cyclin D1 overexpression was also noted in many solid tumors with gene amplification on 11q13.13)

Mantle cell lymphoma (MCL) has been characterized by histopathology, immunophenotyping, t(11;14)(q13;q32) and cyclin D1 overexpression.8, 14, 15) Reliable methods for detection of t(11;14) and/or cyclin D1 overexpression are needed for clinical analysis and management of patients with MCL. Because of a low mitotic index in indolent lymphomas, which have to be distinguished from MCL, chromosome analysis is not always informative, and it is time-consuming. Detection of bcl-1 rearrangement by classical Southern blot analysis or by polymerase chain reaction (PCR) methods is also hampered by the large area within the bcl-1 locus in which rearrangement breakpoints can be located.6, 8, 9, 10) Fluorescence in situ hybridization techniques for detection of t(11;14)(q13;q32)15–22) and immunohistochemistry for cyclin D1 protein detection24–27) appear to be highly diagnostic procedures for MCL.

Recently, we developed a simple assay involving reverse transcription followed by competitive PCR (competitive RT-PCR). This approach allows the detection of cyclin D1 overexpression.28) In this assay, a single upstream primer is derived from a homologous region of the sequences in cyclin D1 and other D-type cyclins, cyclins D2 and D3, while
three downstream primers are specific to their respective D-type cyclins. Because the upstream primer is shared in PCR amplification of the three sequences, each PCR product serves as a competitor and quantification of the target is made by comparing the intensities of the three products. This unique competitive RT-PCR is advantageous in its simplicity, as internal homologous sequences serve as competitors and there is no need for externally prepared competitors. This method is suitable for analysis of clinical specimens, the quality of which is difficult to control. In the present report, we demonstrate the clinical applicability of this competitive RT-PCR, using tissue specimens from patients with lymphoid malignancies.

MATERIALS AND METHODS

Clinical specimens of lymphoid malignancies A total of 104 tissue specimens from 104 Japanese patients with lymphoid malignancies was examined. Most of the specimens had been frozen with dimethyl sulfoxide in liquid nitrogen or in a deep-freeze unit at $-80^\circ$C until RNA preparation, and some were freshly prepared. These patients were selected from the files of the Fourth Department of Internal Medicine, University of Tokyo, School of Medicine (Tokyo) between December 1985 and July 1996, the Department of Hematology, Showa General Hospital (Tokyo) between March 1992 and February 1996, and the Cancer Institute Hospital (Tokyo) between November 1993 and February 1996 on the basis of the availability of frozen or fresh samples for molecular studies. Five patients had been referred from Nagano Red Cross Hospital (Nagano) and Kurobe City Hospital (Toyama).

Table I. Cyclin D1 Overexpression Detected by Competitive RT-PCR in Lymphoid Malignancies

| Disease                        | No. of patients | Cyclin D1 overexpression |
|-------------------------------|-----------------|--------------------------|
| Non-Hodgkin’s lymphoma        |                 |                          |
| B-lineage                     | 55              | 7                        |
| T-lineage                     | 5               | 0                        |
| Unclassified                  | 12              | 0                        |
| Adult T-cell lymphoma/leukemia| 6               | 0                        |
| Hodgkin’s disease             | 4               | 0                        |
| Acute lymphoblastic leukemia  |                 |                          |
| B-lineage                     | 6               | 0                        |
| T-lineage                     | 3               | 0                        |
| Unclassified                  | 2               | 0                        |
| Multiple myeloma              | 4               | 3                        |
| Waldenström’s macroglobulinemia| 2              | 1                        |
| Prolymphocytic leukemia       | 2               | 1                        |
| Chronic lymphocytic leukemia   | 3               | 1                        |
| Total                         | 104             | 13                       |

Fig. 1. Competitive RT-PCR analysis of clinical specimens for cyclin D1 overexpression. Representative results of the competitive RT-PCR analysis are shown, including all patients with cyclin D1 overexpression (positive cases 1–13). RNAs were prepared from patients with B-cell lymphoma (A), multiple myeloma (MM), Waldenström’s macroglobulinemia (WM), B-cell prolymphocytic leukemia (PLL), B-cell chronic lymphocytic leukemia (CLL) (B), peripheral T-cell lymphoma (T-NHL), adult T-cell lymphoma/leukemia (ATL), Hodgkin’s disease (HD), and acute lymphoblastic leukemia (ALL) (C). PCR products were analyzed on 1.2% agarose gels containing ethidium bromide and photographed. Arrows indicate PCR products corresponding to cyclins D1, D2, and D3. DLBL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBL+MCL, diffuse large B-cell lymphoma with mantle cell lymphoma; DLBL<−MCL, diffuse large B-cell lymphoma transformed from mantle cell lymphoma; LPL, lymphoplasmacytoid lymphoma; H2O, negative control without cDNA. The sizes (bp) of 100 bp DNA ladders (Marker) are shown on the left.
The patients (59 men and 45 women) ranged in age from 14 to 89 years (median age: 58 years). Tissues consisted of 72 lymph nodes, 16 bone marrow (BM), 9 peripheral blood (PB), 4 pleural effusion, 2 extranodal tumors and 1 spleen. The lymphoid malignancies in these patients are summarized in Table I. Among them, 14 patients (10 non-Hodgkin’s lymphoma (NHL) containing 2 MCL and 2 lymphoplasmacytoid lymphoma (LPL), 1 acute lymphoblastic leukemia (ALL), 1 multiple myeloma (MM), 1 CLL, and 1 PLL) were reported in our previous study.28) Data on 1 patient with MM29) and 1 patient with PLL30) were from the cited reports. Eighty-one tumors had been characterized in Table I. Among them, 14 patients (10 non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia; DLBL, diffuse large B-cell lymphoma; DLBL+MCL, diffuse large B-cell lymphoma and mantle cell lymphoma; DLBLc<MCL, diffuse large B-cell lymphoma transformed from mantle cell lymphoma; MCL, mantle cell lymphoma; LPL, lymphoplasmacytoid lymphoma; BM, bone marrow; LN, lymph node; PB, peripheral blood; PE, pleural effusion; ND, not done; BJP, Bence Jones protein.

nuclear cells were separated by standard Ficoll-Paque (Pharmacia Biotech, Upsala, Sweden) density-gradient centrifugation as recommended by the manufacturer. Fresh lymph node cells were prepared by sieving minced lymph nodes. RNAs of these cells were also extracted by the AGPC method.

Competitive RT-PCR Competitive RT-PCR was done as described30) but with minor modifications. Briefly, cDNA was synthesized with oligo(dT)$_{15}$ from total RNA and an aliquot (5 µl, 0.1 µg RNA equivalent) of cDNA was placed in 50 µl of 1× PCR buffer (10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl$_2$, pH 8.3) with 200 µM each deoxyribonucleoside triphosphate, 0.2 µM each primer, and 2.5 U of recombinant Taq DNA polymerase (Takara, Kyoto). Reaction parameters were 30 rounds of 94°C for 1 min, 50°C for 2 min, and 72°C for 3 min. The PCR products (10 µl) were electrophoresed on a 1.2% agarose gel containing ethidium bromide. A photograph of the gel was scanned with a ScanTouch (Nikon, Tokyo) and densitometric analysis was done using NIH Image software. The relative expression level of each D-type cyclin was calculated using the following formula: cyclin D1, a/(a+b+c); cyclin D2, b/(a+b+c); cyclin D3, c/(a+b+c); where a is a density of the cyclin D1 PCR product, b is that of the cyclin D2

**Table II. Characteristics of the 13 Patients with Cyclin D1 Overexpression**

| Case No. | Age/ Sex | Disease | Stage | Tissue source | t(11;14) | Surface markers | M protein | CD5 Immunoglobulins | Cyclin D1 | Cyclin D2 | Cyclin D3 | Survival (months) |
|----------|----------|---------|-------|---------------|---------|----------------|-----------|-------------------|-----------|-----------|-----------|------------------|
| 1        | 77/M     | NHL DLBL | III   | BM (o)        | →                                                 | +         | ND               | −       | 0.64 ± 0.20      | 0.16 ± 0.40 | 40        |            |                  |
| 2        | 60/F     | NHL DLBL+MCL | IV    | LN            | +                                                 | +         | IgM, λ           | −       | 0.51 ± 0.26      | 0.22 ± 0.45 | 5         |            |                  |
| 3        | 65/M     | NHL DLBL<–MCL | IV    | LN            | +                                                 | +         | IgM, λ           | −       | 0.59 ± 0.15      | 0.25 ± 0.37 | 21        |            |                  |
| 4        | 72/M     | NHL MCL   | IV    | PB (o)        | →                                                 | +         | ND               | −       | 0.59 ± 0.14      | 0.27 ± 0.39 | 33        |            |                  |
| 5        | 79/M     | NHL LPL   | IV    | BM (o)        | →                                                 | +         | IgM, IgD, λ, IgM-λ, BJ paternal | − | 0.68 ± 0.25 | 0.07 ± 0.37 | 25+       |            |                  |
| 6        | 62/M     | NHL MCL   | IV    | PB            | +                                                 | +         | IgM, IgD, λ     | −       | 0.57 ± 0.16      | 0.27 ± 0.42 | 35+       |            |                  |
| 7        | 66/F     | NHL LPL   | IV    | BM (o)        | →                                                 | –         | –                | −       | 0.71 ± 0.16      | 0.13 ± 0.38 | 18        |            |                  |
| 8        | 60/M     | MM        | IIIb (o) | PE            | +                                                 | –         | –                | −       | 0.71 ± 0.12      | 0.28 ± 0.41 | 21        |            |                  |
| 9        | 51/F     | MM        | IIIb (o) | BM            | +                                                 | –         | –                | −       | 0.60 ± 0.23      | 0.17 ± 0.40 | 14        |            |                  |
| 10       | 79/F     | MM        | IIIb (o) | BM            | →                                                 | –         | –                | −       | 0.37 ± 0.30      | 0.33 ± 0.65 | 8+        |            |                  |
| 11       | 71/M     | WM        | –      | BM            | ND                                               | ND        | IgM, IgG, K, IgM-K | −     | 0.73 ± 0.14      | 0.13 ± 0.37 | 34        |            |                  |
| 12       | 72/M     | PLL       | –      | PB            | +                                                 | +         | IgM, IgD, λ     | −       | 0.58 ± 0.15      | 0.27 ± 0.42 | 42+       |            |                  |

Abbreviations: NHL, non-Hodgkin’s lymphoma; MM, multiple myeloma; WM, Waldenström’s macroglobulinemia; PLL, prolymphocytic leukemia; CLL, chronic lymphocytic leukemia; DLBL, diffuse large B-cell lymphoma; DLBL+MCL, diffuse large B-cell lymphoma and mantle cell lymphoma; DLBLc<–MCL, diffuse large B-cell lymphoma transformed from mantle cell lymphoma; MCL, mantle cell lymphoma; LPL, lymphoplasmacytoid lymphoma; BM, bone marrow; LN, lymph node; PB, peripheral blood; PE, pleural effusion; ND, not done; BJP, Bence Jones protein.

a) The relative expression level of each D-type cyclin was calculated as described in “Materials and Methods.”
b) Durie & Salmon.
c) Rai (Binet).d) BM involvement was evident at recurrence.
e) Clonal cytogenetic abnormalities were not evident.
f) bcl-1 rearrangement was evidenced by Southern blot analysis (data not shown).
product and c is that of the cyclin D3 product. Cyclin D1 overexpression was considered positive when the relative expression level of cyclin D1 exceeded those of cyclins D2 and D3.

Screening of peripheral blood and bone marrow aspirates

We analyzed 103 PB samples and 34 BM aspirates from consecutive patients in the outpatient clinic and in the Department of Hematology in the Branch Hospital, University of Tokyo, School of Medicine. The 103 patients for PB screening included 51 men and 52 women ranging in age from 20 to 84 years (median age: 60 years). There were 13 with active NHL, 2 with adult T-cell lymphoma/leukemia (ATL), 8 with myelodysplastic syndrome, 2 with primary amyloidosis, 8 with myeloproliferative disorders, 1 with CLL, 1 with carcinoma, 1 with signet ring cell carcinoma of the stomach, and 1 with colon cancer; the remaining 66 patients had no active neoplastic disease. The 34 patients for BM screening included 25 men and 9 women ranging in age from 20 to 82 years (median age: 63 years). In 22, there was no BM involvement of neoplastic disease.

One-sixth of RNA derived from 100 µl of peripheral blood or from 50 µl of a bone marrow aspirate was subjected to RT in a volume of 20 µl, and 5 µl of the reaction products was subjected to PCR in a volume of 50 µl. Clinical specimens used in this study were collected after written informed consent had been obtained. Analysis of 20 patients for PB screening and 4 patients for BM screening was reported in our previous paper.28)

RESULTS

Competitive RT-PCR analysis of lymphoid malignancies

As shown in Table I, cyclin D1 overexpression was detected using the competitive RT-PCR assay in 13 of the 104 patients examined. Seven of the 72 NHLs (Fig. 1A), 3 of 4 MM, 1 of 2 Waldenström’s macroglobulinemia (WM), 1 of 2 PLLs, and 1 of 3 CLLs (Fig. 1B) were clearly positive. None of the ATL, Hodgkin’s disease (HD) or ALL specimens showed overexpression of cyclin D1 (Fig. 1C). All positive patients had B-cell malignancies (Table II). Interestingly, cyclin D1 overexpression was frequent in extranodal specimens, especially bone marrow and peripheral blood. Only two of 72 lymph nodes (2.8%) versus 11 out of 32 extranodal specimens (34.4%) were positive. The
Cyclin D1 in Lymphoid Malignancies

Result of cytogenetic analysis was definite for 56 patients, including 35 NHLs, 4 ATLs, 1 HD, 8 ALLs, 4 MMs, 2 PLLs, and 2 CLLs. Bone marrow aspirates from a myeloma patient (MM, case 10) were sequentially analyzed: lane 1, at diagnosis; lane 2, after chemotherapy; lane 3, at the time when tumor regrowth was seen. Case 6 is a patient with mantle cell lymphoma (MCL). BM(+), bone marrow involvement; BM(−), no involvement of bone marrow; RAEB, refractory anemia with excess of blasts; RAEB-T, RAEB in transformation; H2O, negative control. The sizes (bp) of 100 bp DNA ladders (Marker) are shown on the left. Relative expression levels of D-type cyclins are plotted in a diagram. Relative expression levels of D-type cyclins calculated as described in "Materials and Methods" are plotted for each specimen as described in the legend to Fig. 2. Each symbol denotes the following: open square ( ), case 10 at diagnosis ( ), after chemotherapy ( ), and at tumor regrowth ( ); closed circle ( ), case 6; open circle ( ), other patients.

Among NHLs with cyclin D1 overexpression, 2 patients had typical MCL and 3 patients had a diffuse large B-cell lymphoma (DLBL) classified using the revised European-American classification of lymphoid neoplasms. Two were associated with MCL, sequentially or simultaneously. These DLBL cases were CD5-positive lymphomas and should be large-cell or blastic variants of MCL. Almost all patients with cyclin D1 overexpression, including those with multiple myeloma, had advanced disease at the time of diagnosis. The median survival of all positive patients was 21 months from the time of diagnosis.

All patients are mapped according to the relative expression levels of D-type cyclins in the diagram shown in Fig. 2. Cyclin D1 expression is unequivocally predominant in t(11;14)(q13;q32)-bearing B-cell malignancies and/or MCLs (closed symbols in Fig. 2). Major D-type cyclins expressed in other lymphoid malignancies are cyclins D2 and D3, with slightly higher expression levels of cyclin D2 in most of the patients.
positive; thus cyclin D1 overexpression was attributed to myeloma cells. An MCL patient with BM involvement (case 6) could not be considered positive, according to our criteria, probably because the proportion of lymphoma cells in the analyzed BM specimen was small. Therefore, no false positivity was found in PB samples or in BM aspirates.

DISCUSSION

We detected cyclin D1 overexpression in all the patients with t(11;14), using our competitive RT-PCR assay. Some patients without t(11;14) showed overexpression of cyclin D1, according to our criteria. These observations suggest that the potential for detection with this assay is better than with conventional chromosome analysis, because other mechanisms than t(11;14) could lead to cyclin D1 overexpression and/or because chromosome analyses were not informative, probably due to low proliferative rates in these patients or to contamination with normal cells. The assay can be done more rapidly and is less tedious than northern blot analysis and chromosome analysis. This method has higher rates of detection compared to classical Southern blot analysis and PCR methods for the detection of bcl-1 rearrangement.6-19 Rapid and reliable detection of cyclin D1 overexpression with this assay would be a useful complement to fluorescence in situ hybridization techniques,20-23 which are sensitive methods for detection of t(11;14)(q13;q32), and immunohistochemistry for cyclin D1 protein detection,24-27 which appears to be highly diagnostic.

The competitive RT-PCR assay in the present study may show false-positives when tumor cells are mixed with normal cells that express cyclin D1 more than cyclins D2 and D3. However, as shown above, in both PB and BM, relative expression levels of cyclin D1 never exceeded those of cyclins D2 and D3 unless tumor cells overexpressing cyclin D1 were included. Therefore, a leukemic state or BM involvement in NHL is an appropriate situation for application of this assay with high specificity. In fact, MCL is frequently associated with extranodal involvement.15 Furthermore, cyclin D1 overexpression was detected (11 out of 32) in extranodal specimens, especially PB and BM, more frequently than lymph nodes (2 of 72). Although there was some selection bias, our observations suggest direct or indirect association of cyclin D1 overexpression with extranodal distribution of tumor cells.

Theoretically speaking, with the expression of cyclins D2 and D3 genes used as internal controls, our assay quantifies the relative expression level of cyclin D1 not the absolute expression level. Therefore, false-positives may occur if cyclins D2 and D3 are downregulated. However, as shown above, in practice, no apparent false-positive was found and the assay was useful for screening for cyclin D1 overexpression.

The sensitivity of this assay was previously determined so that 50% or more tumor cells are required for definite detection of cyclin D1 overexpression. In the present study, such sensitivity was again confirmed by sequential analysis of the patient with myeloma (case 10). Provided that tumor cells are a major component of a clinical specimen, a small aliquot of the sample is sufficient for detection of cyclin D1 overexpression, using this assay.

Dewald et al. reported that t(11;14)(q13;q32) was detected in 3% of plasma cell disorders (MM, plasma cell leukemia, and amyloidosis) and that it was the single most common abnormality.9 In the current study, 3 of 4 myeloma patients had cyclin D1 overexpression and 2 had t(11;14). One patient was referred because of t(11;14) and two other positive patients might have been selected by chance. However, the reason for the high frequency might be that MM with t(11;14) tends to be aggressive9,20 and that the opportunity to collect and store such myeloma cells might have been greater. To our knowledge, no sizable studies on cyclin D1 overexpression in MM have been documented. With our assay, which is suitable for a large series of cases, the incidence of cyclin D1 overexpression could be easily clarified and might turn out to be much higher than the 3% determined by chromosome analysis, which could be hampered by low proliferation in the disease.

The types of lymphoid malignancies determined to overexpress cyclin D1 by our assay were identical with those previously reported for t(11;14)(q13;q32), bcl-1 rearrangement and/or cyclin D1 overexpression with other methods.8-10,12,19,34-36 Heterogeneity of B-lymphoid malignancies associated with cyclin D1 overexpression was again confirmed. Thus, detection of cyclin D1 overexpression is not sufficient for the diagnosis of MCL. Relationships among these malignancies, i.e., MCL, LPL, MM, CLL and PLL, remain to be investigated.

Quantitative RT-PCR requires well-controlled conditions and good-quality RNA because of the exponential character of the reaction. Clinical specimens are sometimes difficult to preserve under good conditions and are not appropriate for conventional competitive RT-PCR. However, the present study shows that PCR can be used to detect oncogene overexpression in clinical specimens of variable quality. Competition with internally expressed homologous sequences would make quantitative PCR more reliable and simpler than conventional methods.

In conclusion, the competitive RT-PCR assay we have developed is reliable and provides clinical guidance in the diagnosis and management of lymphoid malignancies, especially in cases of extranodal involvement. It remained to be determined if this assay can detect cyclin D1 overexpression in solid tumors with gene amplification at 11q13.
REFERENCES

1) Sherr, C. J. G1 phase progression: cycling on cue. Cell, 79, 551–555 (1994).
2) Sherr, C. J. Mammalian G1 cyclins. Cell, 73, 1059–1065 (1993).
3) Xiong, Y., Menninger, J., Beach, D. and Ward, D. C. Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics, 13, 575–584 (1992).
4) Motokura, T., Keyomarsi, K., Kronenberg, H. M. and Arnold, A. Cloning and characterization of human cyclin D3, a CDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J. Biol. Chem., 267, 20412–20415 (1992).
5) Motokura, T., Bloom, T., Kim, H. G., Jupner, H., Ruderman, J. V., Kronenberg, H. M. and Arnold, A. A novel cyclin encoded by a bcl-1-linked candidate oncogene. Nature, 350, 512–515 (1991).
6) Withers, D. A., Harvey, R. C., Faust, J. B., Melnyk, O., Carey, K. and Meeker, T. C. Characterization of a candidate bcl-1 gene. Mol. Cell. Biol., 11, 4846–4853 (1991).
7) Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L. and Arnold, A. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc. Natl. Acad. Sci. USA, 88, 9638–9642 (1991).
8) Raffeld, M. and Jaffe, E. S. bcl-1, t(11;14), and mantle cell lymphoma — An entity comes of age. Blood, 87, 4483–4494 (1996).
9) Dewald, G. W., Kyle, R. A., Grogan, J. A., and Simons, M. P. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chrom. Cancer, 8, 80–87 (1993).
10) Nishida, K., Taniwaki, M., Misawa, S. and Abe, T. Nonrandom rearrangement of chromosome 1q at band q32.33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res., 49, 1275–1281 (1989).
11) Brito-Babapulle, V., Pittman, S., Melo, J. V., Pomfret, M. and Catovsky, D. Cytogenetic studies on polylymphocytic leukemia i. B-cell polylymphocytic leukemia. Hematol. Pathol., 1, 27–33 (1987).
12) Newman, R. A., Peterson, B., Davey, F. R., Braby, C., Collins, H., Brunetto, V. L., Duggan, D. B., Weiss, R. B., Royston, I., Millard, F. E., Miller, A. A. and Bloomfield, C. D. Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a cancer and leukemia group B study. Blood, 82, 1239–1246 (1993).
13) Motokura, T. and Arnold, A. Cyclins and oncogenesis. Biochim. Biophys. Acta, 1155, 63–78 (1993).
14) Banks, P. M., Chan, J., Cleary, M. L., Delsol, G., Wolf-
24) Yang, W. I., Zukerberg, L. R., Motokura, T., Arnold, A. and Harris, N. L. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. *Am. J. Pathol.*, **145**, 86–96 (1994).

25) Nakamura, S., Seto, M., Banno, S., Suzuki, S., Koshikawa, T., Kito, K., Kagami, Y., Ogura, M., Yatabe, Y., Kojima, M., Motoori, T., Takahashi, T., Ueda, R. and Suchi, T. Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. *Jpn. J. Cancer Res.*, **85**, 1270–1279 (1994).

26) de Boer, C. J., Schuuring, E., Dreef, E., Peters, G., Bartek, J., Kluin, P. M. and van Krieken, J. H. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. *Blood*, **86**, 2715–2723 (1995).

27) Yatabe, Y., Nakamura, S., Seto, M., Kuroda, H., Kagami, Y., Suzuki, R., Ogura, M., Kojima, M., Koshikawa, T., Ueda, R. and Suchi, T. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. *Am. J. Surg. Pathol.*, **20**, 1110–1122 (1996).

28) Uchimaru, K., Taniguchi, T., Yoshikawa, M., Asano, S., Arnold, A., Fujita, T. and Motokura, T. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma. *Blood*, **89**, 965–974 (1997).

29) Kobayashi, H., Saito, H., Kitano, K., Kiyosawa, K., Gaun, S., Aoki, K., Narita, A., Watanabe, M., Uchimaru, K. and Motokura, T. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32). *Acta Haematol.*, **94**, 199–203 (1995).

30) Kobayashi, H., Kitano, K., Saito, H., Aoki, K., Narita, A., Terada, N., Sonoyama, M., Uchimaru, K., Machii, T. and Motokura, T. Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). *Cancer Genet. Cytogenet.*, **84**, 69–72 (1995).

31) Chomczynski, P. and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.*, **162**, 156–159 (1987).

32) Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K., Cleary, M. L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K. C., Grogan, T. M., Isaacson, P. G., Knowles, D. M., Mason, D. Y., Muller-Hermelink, H.-K., Pileri, S. A., Piris, M. A., Ralfkiaer, E. and Warnke, R. A. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood*, **84**, 1361–1392 (1994).

33) Delner, A., Ajchenbaum-Cymbalista, F., Tang, R., Ramond, S., Faussat, A. M., Marie, J. P. and Zattoun, R. Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. *Br. J. Haematol.*, **89**, 798–804 (1995).

34) Jadayel, D., Matutes, E., Dyer, M. J., Brito-Babapulle, V., Kohokar, M. T., Oscier, D. and Catovsky, D. Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene. *Blood*, **83**, 3664–3671 (1994).

35) Rimokh, R., Berger, F., Delsol, G., Charrin, C., Bertheas, M. F., Fitrench, M., Garoscio, M., Felman, P., Coiffier, B., Bryon, P. A., Rochet, M., Gentilhomme, O., Germain, D. and Magaud, J. P. Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. *Blood*, **81**, 3063–3067 (1993).

36) Bosch, F., Jares, P., Campo, E., Lopez-Guillermo, A., Piris, M. A., Villamor, N., Tassies, D., Jaffe, E. S., Montserrat, E., Rozman, C. and Cardesa, A. PRAD1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. *Blood*, **84**, 2726–2732 (1994).